DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Pharmacokinetic Study Of EPZICOM Tablet

Information source: GlaxoSmithKline
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: HIV Infection

Intervention: Lamivudine / Abacavir Sulfate (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, MD, Study Director, Affiliation: GlaxoSmithKline


This study was designed to explore the drug levels in the blood in Japanese HIV-infected patients taking EPZICOM tablet at least for 2 weeks prior to administration of the study drug. Pharmacokinetics after administration of EPZICOM tablet will be investigated in a total of 8 subjects.

Clinical Details

Official title: Post-Marketing Clinical Study of EPZICOM Tablet (Lamivudine / Abacavir Sulfate) - Pharmacokinetic Study in HIV-Infected Patients -

Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacokinetics Study

Primary outcome: The following pharmacokinetic parameters of plasma lamivudine and abacavir Maximum plasma concentration(Cmax), Time to the maximum plasma concentration(tmax), Elimination half-life(t1/2), Area under the plasma concentration-time curve(AUC)

Secondary outcome: Safety (adverse events occurring during the study period)


Minimum age: 20 Years. Maximum age: 64 Years. Gender(s): Both.


Inclusion criteria:

- A Japanese HIV-infected patient who continues to use one EPZICOM tablet in the morning

(00: 00 to 12: 00) at least for 2 weeks prior to administration of the study drug.

- A patient who agrees to abstain from alcohol from 48 hours prior to administration of

the study drug until completion of blood sampling for pharmacokinetic analysis.

Exclusion criteria:

- A patient developing AIDS (Patients who developed AIDS in the past but have no

symptoms or findings that may serve as indicators at screening may be eligible for the study.)

- A patient with a history of hypersensitivity to the study drug and the ingredients

(lamivudine, abacavir sulfate) of the study drug

Locations and Contacts

GSK clinical trials call center, Nagano 384, Japan

GSK clinical trials call center, Shizuoka 432, Japan

Additional Information

Starting date: May 2006
Last updated: November 12, 2007

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015